MGNX: MacroGenics, Inc. Stock

by  •  • Comments Off on MGNX: MacroGenics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 180.76
Enterprise Value ($M) 1.13
Book Value ($M) 120.07
Book Value / Share 1.91
Price / Book 1.51
NCAV ($M) 77.77
NCAV / Share 1.24
Price / NCAV 2.32

Profitability (mra)
Return on Invested Capital (ROIC) -0.63
Return on Assets (ROA) -0.33
Return on Equity (ROE) -0.64

Liquidity (mrq)
Quick Ratio 3.69
Current Ratio 3.75

Balance Sheet (mrq) ($M)
Current Assets 222.20
Assets 264.49
Liabilities 144.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Bb Biotech Ag
02-14 13G/A Armistice Capital, Llc
02-14 13G/A Ra Capital Management, L.p.
02-11 13G Wasatch Advisors Inc
11-20 13G Frazier Life Sciences Public Fund, L.P. 5.10
11-08 13G/A BlackRock, Inc. 8.60 0.00
06-04 13G Millennium Management Llc 5.10 18.68
2024-02-14 13G T. Rowe Price Investment Management, Inc. 9.10
2024-02-13 13G/A Vanguard Group Inc 6.95 -3.04

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT
2024-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 79,525 500,994 15.87
2025-02-20 47,873 433,684 11.04
2025-02-19 136,315 611,160 22.30
2025-02-18 148,534 1,188,522 12.50

(click for more detail)

Similar Companies
LYEL – Lyell Immunopharma, Inc. MCRB – Seres Therapeutics, Inc.
MDGL – Madrigal Pharmaceuticals, Inc. MGTX – MeiraGTx Holdings plc
MIST – Milestone Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io